Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1.

The mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways are activated during pathogenesis of gastrointestinal stromal tumors (GISTs). Forkhead box protein O1 (FOXO1) is a transcription factor regulated by the MAPK and PI3K pathways and is associated with multiple metabolic reactions. The present study aims to investigate the association of FOXO1 with cell proliferation and apoptosis in the cell line, GIST-T1. Cell counting kit-8 assay revealed that cell growth was inhibited by the PI3K inhibitor, LY294002, and/or MAPK inhibitor, UO126. Western blotting demonstrated that the expression of p-FOXO1 and B-cell lymphoma 2 (Bcl2) were significantly reduced, whereas the expression of Bcl-2-associated X protein was significantly increased following treatment with LY294002 and/or UO126 (all P<0.05). However, no significant change was revealed in the level of total FOXO1. Flow cytometry revealed that apoptosis was significantly increased by the pathway inhibitors (P<0.05). Specifically, the proportion of cells in the G1 phase was increased whereas the proportion in the S phase was reduced. The changes of protein expression and cell apoptosis were more evident in the LY294002 + UO126 group than in either single-inhibitor group. The results indicated that FOXO1 was able to affect cell proliferation, apoptosis and the cell cycle of GISTs. The regulation of FOXO1 was part of the PI3K and MAPK signaling network, while this regulation was mostly activated by phosphorylation of FOXO1.

Introduction

Gastrointestinal stromal tumors (GISTs) were initially classified by Mazur and Clark in 1983 (1), and represent a wide spectrum of mesenchymal tumors in the entire gastrointestinal tract (2). GISTs are most commonly observed in the stomach and small intestine, followed by the colon, rectum and esophagus. They typically occur in individuals >50 years old and the incidence of GISTs is 10–20 individuals in a million (3). A notable feature of GISTs is that mutations within the KIT or platelet-derived growth factor receptor (PDGFR) genes exist in the majority of cancer cells (4). Normally, c-KIT activation requires binding to its ligand, stem cell factor (SCF). Interaction between c-KIT and SCF activates a cascade of downstream reactions, whereas mutations in the KIT gene lead to uncontrolled activation of the tyrosine kinase domain and promoted cell proliferation (5). Activation of KIT is crucial for the pathogenesis of the majority of GISTs (6), which makes this oncoprotein a potential therapeutic target. Furthermore, imatinib and other tyrosine kinase inhibitors are typically used to treat GISTs (7).

The downstream signaling pathways that are known to be activated by KIT include the RAS/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B networks (8,9). Forkhead box protein O1 (FOXO1) is a member of the FOXO transcription factors, which has been demonstrated to be closely associated with cell apoptosis, DNA damage or repair, cell autophagy, oxidative stress, angiogenesis and sugar metabolism (10–12). Furthermore, the PI3K and MAPK networks are key signaling pathways that regulate FOXO1 expression (13). A previous study demonstrated that high expression of FOXO1 is able to inhibit cell proliferation (14). However, the potential association of FOXO1 expression in GISTs remains unclear. The present study was designed to investigate the regulatory mechanism by which the PI3K and MAPK signaling pathways influence the activity of FOXO1 and its downstream factors, B-cell lymphoma 2 (Bcl2) and Bcl-2-associated X protein (Bax).

Materials and methods

Reagents

The PI3K inhibitor, LY294002 hydrochloride (cat. no. L9908) and the MAPK inhibitor, UO126 monoethanolate (cat. no. U126) were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Rabbit monoclonal antibody to c-Kit was purchased from Abcam (cat. no. ab32363; Cambridge, MA, USA). Rabbit monoclonal antibodies to FOXO1 (cat. no. 2880S), phosphorylated (p)-FOXO1 (s256, cat. no. 84192S), Bcl2 (cat. no. 4223S) and Bax (cat. no. 5023S) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Mouse anti-β-actin (cat. no. sc-47778), horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG; cat. no. sc-2030) and HRP-conjugated goat anti-mouse IgG (cat. no. sc-2055) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Tetramethylrhodamine-conjugated donkey anti-human IgG (cat. no. D110143) and cell counting kit-8 (CCK-8 kit; cat. no. E606335) were purchased from Sangon Biotech Co., Ltd. (Shanghai, China). The MaxVision immunohistochemistry kit (cat. no. KIT-5002) was purchased from Fuzhou Maixin Biotech Co., Ltd. (Fuzhou, China). DAPI (cat. no. 10236276001) was purchased from Roche Diagnostics (Basel, Switzerland). The GIST-T1 gastrointestinal stromal tumor cell line was purchased from Biowit Technologies, Ltd. (Shenzhen, China) and the WI-38 normal lung fibroblast cell line was obtained from Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The media used for cell culture [Dulbecco's modified Eagle's medium (DMEM), minimum essential media (MEM) and fetal calf serum] were purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Cell culture and treatments

GIST-T1 cells, characterized in detail by Taguchi et al (15), were cultured in DMEM and WI-38 cells (ATCC® CCL-75™) in MEM. Both media were supplemented with 10% fetal calf serum and maintained at 37°C in a humidified atmosphere containing 5% CO2 and 95% air. The GIST-T1 cells were maintained in the log-growth phase and treatment groups were treated with 30 µM LY294002 (LY294002 group), 10 µM UO126 (UO126 group) or 30 µM LY294002 + 10 µM UO126 (LY+UO group) at 37°C for 24 h. An equal amount of dimethylsulfoxide (DMSO) was added into the control group and incubated at 37°C for 24 h.

Immunocytochemistry and immunofluorescence staining

GIST-T1 cells were seeded into six-well chamber slides at a density of 1×104 cells/well and allowed to adhere. Subsequently, 1 ml medium was added to each well and cultures were maintained at 37°C for 24 h, then washed and fixed with acetone at 4°C for 20 min. Cells were permeabilized with 0.5% Triton X-100 for 20 min. To inhibit endogenous peroxidase activity, slides were incubated at 37°C with 3% H2O2 for 10 min, washed with PBS and blocked with 5% bovine serum albumin (Biosharp, Anhui, China) at room temperature for 30 min. Excess serum was removed with filter paper, and the primary c-Kit antibody (1:500) was added and incubated at 4°C overnight. Following washing three times with PBS for 5 min each, the HRP-labeled Goat Anti-Mouse IgG (1:50) or DyLight 405-labeled Goat Anti-Mouse IgG (1:200) was added and incubated at room temperature for 30 min and washed three times with PBS for 5 min each. For peroxidase staining, color was developed using 3,3′-diaminobenzidine, slides were washed to terminate the reaction and then nuclei were counterstained with hematoxylin at room temperature for 30 sec. For immunofluorescence staining, nuclei were counterstained with DAPI at room temperature for 15 min, slides were dried and then sealed with neutral resin. Slides were observed under a light or a fluorescence microscope (magnification, ×400) and images were captured.

CCK-8 cell proliferation assay

A single-cell suspension of GIST-T1 was seeded into 96-well plates at 1×105 cells per well and treated with inhibitors as described above. Following treatment for 0, 12, 24, 36 or 48 h, 10 µl CCK-8 reagent was added, samples were incubated at 37°C and 5% CO2 for 1 h and agitated gently to ensure any precipitate was dissolved. The absorbance of each well was measured with a microplate reader, at an absorption wavelength of 450 nm. With the measured optical densities (ODs), the following formula was used: Inhibition ratio (%)=(OD value of control group-OD value of experimental group)/OD value of control group ×100.

Western blotting

Cell cultures were treated as described above. At the end of the culture period, the total protein was extracted from the cells in 100 µl extraction buffer (10 mM Tris, 1 mM EDTA, 1% SDS, 0.1% Triton X-100 containing complete protease inhibitor cocktail). A bicinchoninic acid protein assay kit (Pierce; Thermo Fisher Scientific, Inc.) was used to estimate the protein content of the lysate with bovine serum albumin used as the standard. SDS loading buffer [63 mM Tris-HCl, 10% glycerol, 2% SDS, 0.0025% bromophenol blue, (pH 6.8)] was added following normalization of the concentration of protein in each sample with 1% SDS. Protein lysates (30 µg) were separated by 8% SDS-PAGE and electrophoretically transferred onto PVDF membranes (EMD Millipore, Billerica, MA, USA). Membranes were blocked with 5% non-fat dry milk (w/v) in TBST buffer (10 mM Tris, 150 mM NaCl, 0.05% Tween-20) at room temperature for 1 h, and incubated overnight with primary antibodies against FOXO1 (1:1,000), p-FOXO1 (s256; 1:1,000), Bcl2 (1:1,000), Bax (1:1,000) or β-actin (1:2,000) at 4°C. Subsequently, blots were washed three times with TBST and incubated with HRP-conjugated secondary antibody against IgG (1:3,000) at room temperature for 1 h. Enhanced chemiluminescence substrate followed by exposure within an EpiChemi II darkroom (UVP, Inc., Upland, CA, USA) was used for visualization of the protein bands. Quantity One software v4.62 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to analyze the bands and quantify the signal.

Apoptosis assay by flow cytometry

Cultured GIST-T1 cells were treated and collected as described above. Apoptosis was analyzed to investigate whether LY294002 and UO126 were able to enhance cell killing sensitivity. The apoptotic rates were measured using a flow cytometric assay. Cell labeling was performed using Annexin V conjugated to fluorescein isothiocyanate (FITC), which binds to phosphatidylserine exposed on the surface membrane of cells undergoing apoptosis. Cells were collected by trypsinization, washed twice with PBS and centrifuged at 500 × g, room temperature for 5 min. The cells were then suspended in 500 µl PBS and incubated with 5 µl Annexin V-FITC (Annexin V-FITC Apoptosis Detection Kit; Beyotime Institute of Biotechnology, Haimen, China) and 10 µl (20 µg/ml) propidium iodide (PI) solution (Beyotime Institute of Biotechnology) at room temperature for 20 min in the dark. The samples were then measured using a flow cytometer with FACS 101 software (BD Biosciences, Franklin Lakes, NJ, USA). For each sample, 105 fluorescence signals were measured.

Cell cycle distribution assay by flow cytometry

GIST-T1 cells were treated and collected as described above, then fixed in 75% ethanol for 2 h at 4°C. Samples were rehydrated with PBS and incubated with 500 µl (200 µg/ml) PI solution for 30 min at room temperature. For each sample the percentages of cells in the G0/G1, S and G2/M phases of the cell cycle were calculated using a flow cytometer with FACS software. For each sample, 10,000 fluorescence signals were measured.

Statistical methods for data analysis

SPSS 20.0 software (IBM Corp., Armonk, NY, USA) was used for statistical analysis of experimental data. The results are expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference. Differences between groups were determined by one-way analysis of variance with Dunnett's post hoc test.

Results

Confirmation of cell type by immunocytochemistry

Immunocytochemical staining of cultured GIST-T1 cells with an anti-c-Kit antibody revealed brown granules in the cytoplasm (Fig. 1). The presence of this gastrointestinal stromal tumor cell marker indicated that the cells cultured in the present study were from a gastrointestinal stromal tumor.

Figure 1.

Immunocytochemical staining of cultured GIST-T1 cells. (A) Gastrointestinal stromal tumor cell marker c-Kit was negative in the control group (with PBS replacing the c-kit antibody). (B) Positive staining for the gastrointestinal stromal tumor cell marker c-Kit was observed in the experimental group. Magnification, ×400.

Cell proliferation is inhibited by signaling inhibitors

CCK-8 staining revealed that the inhibition of cell proliferation was enhanced with treatment time in the LY+UO group (P<0.05; Fig. 2). Inhibition of cell proliferation inhibition in the LY+UO group was more pronounced compared with groups treated with either inhibitor alone (P<0.05; Fig. 2). Furthermore, maximal inhibition was observed when cultures were treated with LY294002 or UO126 for 24 h, whereas inhibition peaked at 36 h in the LY+UO group, at which time-point the majority of cells were dead (Fig. 2).

Figure 2.

Cell Counting Kit-8 assay was used to evaluate the growth inhibition of GIST-T1 cells treated with phosphoinositide 3-kinase inhibitor LY294002, mitogen-activated protein kinase inhibitor UO126, and a combination of LY294002 + UO126. Error bars indicate the standard deviations. *P<0.05 and **P<0.01 vs. 0 h; #P<0.05 and ##P<0.01 vs. LY294002; ∆P<0.05 and ∆∆P<0.01 vs. UO126. LY+UO, LY294002 + UO126.

Western blotting analysis

Western blotting revealed that the expression of FOXO1 and Bax significantly decreased, whereas p-FOXO1 and Bcl2 significantly increased in GIST-T1 cells compared with the normal human fibroblasts WI-38 (P<0.05; Fig. 3A). To confirm that protein expression was regulated via the PI3K or MAPK pathways, the cells were treated with pathway inhibitors. The protein expression of p-FOXO1 and Bcl2 was significantly decreased (both P<0.05), whereas Bax (P<0.05) increased in cells treated with LY294002, UO126 or both compared with controls. The reduction in the expression of p-FOXO1 and Bcl2 and the increase in protein expression of Bax were more marked in the LY+UO group; however, total FOXO1 protein expression was not significantly different among the groups treated with LY294002, UO126, LY+UO or DMSO (Fig. 3B).

Figure 3.

(A) Western blotting was used to analyze the protein expression of FOXO1, p-FOXO1, Bcl2 and Bax in GIST-T1 and WI-38 cells (normal human fibroblasts). *P<0.05 vs. WI-38 cells. (B) Western blotting was used to analyze protein expression of FOXO1, p-FOXO1, Bcl2 and Bax in cells treated with LY294002 and UO126 alone or in combination. *P<0.05 vs. DMSO. Error bars indicate the standard deviations. FOXO1, forkhead box protein O1; p, phosphorylated; Bcl2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; DMSO, dimethylsulfoxide; LY+UO, LY294002 + UO126.

Immunofluorescence staining of FOXO1 distribution

Immunofluorescence staining revealed that FOXO1 was widely distributed in the nucleus and cytoplasm in the DMSO group. Treatment of GIST-T1 cells with LY294002 or UO126 resulted in cytoplasmic levels of FOXO1 being markedly reduced, with a corresponding increase in nuclear FOXO1. Furthermore the degree of FOXO1 translocation to the nucleus in the LY+UO group was more pronounced than in either single-inhibitor group (Fig. 4).

Figure 4.

Immunofluorescence to detect the localization of FOXO1 in GIST-T1 cells treated with LY294002 and UO126 alone or in combination. Magnification, ×400. FOXO1, forkhead box protein O1; DMSO, dimethylsulfoxide; LY+UO, LY294002 + UO126.

Apoptosis is induced by signaling inhibitors

Cells in the control group exhibited an apoptosis rate of 1.17±0.21%. In the LY294002-treatment group the apoptosis rate was 2.05±0.32% whereas in the UO126-treated group it was 2.66±0.53%. Additionally, in the LY+UO group the apoptosis rate was 3.82±0.47%. These results demonstrated a significantly increased apoptosis rate (P<0.05) when treating GIST-T1 cells with LY294002 or UO126, and the effect of combined treatment was higher than that of either inhibitor alone (Fig. 5).

Figure 5.

Apoptosis of GIST-T1 cells treated with LY294002 and UO126 alone or in combination. DMSO, dimethylsulfoxide; LY+UO, LY294002 + UO126.

Signaling inhibitors alter the cell cycle distribution

Flow cytometry revealed that the proportion of G0/G1 phase cells in the LY294002, UO126 and LY+UO groups was 79.78±5.27, 73.73±4.86 and 87.28±6.27%, respectively. These proportions were increased significantly compared with the control group at 65.43±4.35% (all P<0.05). The percentages of S phase cells in three treatment groups were 18.65±2.17, 26.27±3.14 and 12.6±1.73%, respectively. The percentages were also significantly decreased compared with the control group (32.17±3.10%; P<0.05). The effect of combination treatment was significantly greater than either inhibitor alone (Fig. 6; all P<0.05).

Figure 6.

Cell cycle distribution of GIST-T1 cells treated with LY294002 and UO126 alone or in combination. DMSO, dimethylsulfoxide; LY+UO, LY294002 + UO126.

Discussion

The pathogenesis of GISTs is closely associated with uncontrolled cell proliferation and inhibition of apoptosis (16). The PI3K and MAPK pathways serve a vital role in the pathogenesis of GISTs (17). Hyperactivation of the PI3K pathway is associated with constitutive autophosphorylation of c-KIT and cancer growth (9). The present study confirmed that the PI3K and MAPK pathways were associated with cell proliferation and apoptosis, and the cell cycle of GISTs. Furthermore, a previous study indicated that the activation of these pathways may be differential. However, the PI3K pathway appears to be activated to a greater extent than the MAPK pathway in wild-type GIST tissues and PDGFR mutants (17). Additionally, activation of the PI3K pathway, rather than the MAPK pathway, was also associated with drug-resistance to imatinib in GISTs (18). The results of the present study demonstrated that the PI3K inhibitor, LY294002, had a stronger growth inhibition effect than the MAPK inhibitor, UO126. However, the regulatory effect of p-FOXO1, Bcl2 and Bax was more evident by UO126 than by LY249002. The difference between phenotypes and molecular expression indicated that regulation of other molecules may also be responsible.

The PI3K and MAPK signaling pathways are important regulators of FOXO1 (13). FOXO1 is an important transcription factor that is associated with the regulation of cell proliferation and apoptosis. The results revealed, that compared with normal fibroblasts, total FOXO1 was suppressed and p-FOXO1 was increased in GIST cells. These results indicated that regulation of FOXO1 was associated with GISTs. Furthermore, a recent study also reported that downregulation of FOXO1 promoted cell proliferation in cervical cancer (11). The activity of FOXO1 may be regulated by phosphorylation, acetylation and other modifications (11). The results of the present study indicated that the PI3K and MAPK pathways regulated FOXO1 by phosphorylation rather than by changing the expression level. Similar results have also been reported previously where studies have demonstrated that the PI3K and MAPK inhibitors were able to inhibit the phosphorylation of FOXO1 and its translocation to the nucleus, and thereby inhibit the transcriptional activity of FOXO1 on downstream factors (19–21).

Previous studies have demonstrated that FOXO1 is associated with the regulation of Bcl2, Bax and other apoptosis-related factors (13,22). Furthermore, overexpression of Bcl2 inhibits apoptosis, whereas overexpression of Bax is able to promote apoptosis (23). Phosphorylated FOXO1 is able to upregulate Bcl2 and downregulate Bax expression to inhibit apoptosis (24,25). Consistent with those previous reports, an increased Bcl2 expression and suppressed Bax expression along with increased p-FOXO1 was also observed in GIST-T1 cells in the present study. However, treating GIST-T1 cells with LY249002 and UO126 was able to inhibit the activation of FOXO1 into p-FOXO1, and thereby lead to increased apoptosis rate and arrested cell cycle at the G0/G1 phase.

In conclusion, regulation of FOXO1 by the PI3K and MAPK pathways was associated with the pathogenesis of GISTs. The downregulation of total FOXO1 and hyperactivation of p-FOXO1 was associated with cell proliferation, apoptosis rate and altered cell cycle in GIST-T1 cells. Furthermore, the phosphorylation of FOXO1 was activated by the PI3K and MAPK pathways. Therefore, further study of the role of the transcription factor FOXO1 in GISTs is required, as it may provide a novel direction for the development of targeted therapy drugs.